Pfizer Inc.'s crizotinib has provided POC that targeting ALK can significantly improve response in a small subset of non-small cell lung cancer patients compared to current treatments. While the pharma completes it NDA submission, other companies are lining up behind it with second-generation programs that they believe will be more selective and more potent.
In January, Pfizer began submission of a rolling NDA to FDA for crizotinib (PF-02341066). It is an oral small molecule dual inhibitor of c-Met receptor tyrosine kinase and anaplastic lymphoma kinase (ALK) and their oncogenic variants.
According to Darrel Cohen, senior director of oncology clinical development, the pharma originally planned to develop the small molecule based on its c-Met inhibitory properties because "we